Accepted at 7:31 p.m. Apr, 30, 2024 by herstein.jacob
Author: GGez
Co-authors: herstein.jacob
Related Note: 1488765239779
Rationale for change

PER STAT PEARLS:

"The onset of action: The onset of action is typically 24 to 72 hours. A peak therapeutic effect is seen 5 to 7 days after initiation. However, the patient's international normalized ratio (INR) may increase within 36 to 72 hours after initiating treatment."

PER UTD:

"Thus, the desired anticoagulant effect of a VKA does not occur for at least three days after drug initiation despite prolongation of the prothrombin time (PT) at earlier time points."

The information in this card also conflicts with another Zanki card which states onset of warfarin takes days not hours.

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step2_v12::#SketchyIM::02_ECG_Interpretation_&_Arrhythmias::04_Tachycardia::04_Narrow_Complex_Tachycardia:_AFib_&_AFlutter_Management #AK_Step1_v12::#Low/HighYield::3-HighYield-temporary #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::02_Warfarin #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::02_Warfarin #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Step1_v12::#UWorld::COMLEX::26751 #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::10_Anticoagulation #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::05_Anticoagulants::Extra #AK_Step1_v12::#UWorld::#UWSA1 #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::07_Anticoagulant_Drugs #AK_Step1_v12::#UWorld::Step::6481 #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::03_Heparin_vs_warfarin::*Warfarin #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::01_Bleeding_&_Clotting_Disorders::01_Bleeding_Disorders:_Coagulation_Factor_Disorders_DDx #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::01_Warfarin #AK_Step1_v12::#AMBOSS::M5aMkO #AK_Step1_v12::#UWorld::Step::18688 #AK_Step1_v12::#AMBOSS::lQavw4